Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 90009530

Drug Profile

JNJ 90009530

Alternative Names: Anti-CD20 CART cells; Anti-CD20 CART-transduced T cells - AbelZeta Pharma; Anti-CD20 chimeric antigen receptor T cell therapy - AbelZeta Pharma; C-CAR066; CAR-CD20 T cell therapy; CAR066; CAR066 CAR; CART20; CBM-C20.1; CBM-CD20 1; Genetically engineered lymphocyte therapy - AbelZeta Pharma; JNJ-90009530

Latest Information Update: 18 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chinese PLA General Hospital
  • Developer AbelZeta Pharma; Chinese PLA General Hospital; Institute of Hematology & Blood Diseases Hospital; Janssen Biotech
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II B-cell lymphoma; Leukaemia
  • Phase I Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 14 Dec 2023 AbelZeta receives IND approval from USFDA for JNJ 90009530 for diffuse large B-cell lymphoma
  • 12 Dec 2023 Pooled efficacy and adverse events data from phase I trials in non-Hodgkin's lymphoma released by AbelZeta Pharma
  • 09 Dec 2023 Pharmacokinetics, pharmacodynamics, efficacy and adverse events data from a phase I trial in B-cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top